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ABSTRACT 28 
Background: vitamin/mineral (VMS) and dietary supplements (DS) use is common in Switzerland, but 29 
nothing is known regarding the factors associated with their initiation, discontinuation or continuation of 30 
intake. 31 
Methods: prospective study conducted between 2003-6 and 2009-12 in Lausanne, Switzerland among 4676 32 
participants (2525 women, age range 35-75 years). VMS were defined as single or 33 
multivitamin/multimineral preparations; DS were defined as any dietary supplement. 34 
Results: VMS use was 20.6% at baseline and 20.3% at follow-up (p=0.69): 559 (12.0%) participants 35 
discontinued; 545 (11.7%) initiated and 404 (8.6%) continued VMS use. On multivariable analysis, men had 36 
a lower relative risk ratio (RRR) of discontinuing, initiation or continuing; older age and being physically 37 
active were associated with a higher RRR of initiation or continuing; lower education and higher body mass 38 
index were associated with a lower RRR of discontinuing or continuing of VMS. 39 
DS use decreased from 10.4% to 6.8% (p<0.001): 405 (8.7%) participants discontinued; 239 (5.1%) initiated 40 
and 81 (1.7%) continued DS use. On multivariable analysis, men had a lower RRR of discontinuing, 41 
initiation or continuing; older age had a higher RRR of initiation, discontinuing or continuing; being 42 
physically active was associated with a higher RRR of initiation or continuing; Swiss citizens and former 43 
smokers had a higher RRR of discontinuing. 44 
Conclusion: VMS use is stable in the Lausanne population, while DS use appears to be decreasing. 45 
Individuals can be categorized either as users or non-users depending on the study period, and consistent 46 
users are only a small fraction of prevalent users. 47 
Abstract word count: 249 48 
Keywords: supplements; epidemiology; prospective study; discontinuing; persistence; Switzerland. 49 
50 
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INTRODUCTION 51 
Vitamin and mineral supplements (VMS) are taken by a significant fraction of the general population 52 
1-5, although their health benefits are questionable 6-8. If some VMS might be of interest (i.e. iron for anaemia 53 
and calcium/vitamin D for osteoporosis), several studies suggested that VMS either have no effect 9 or even 54 
increase total mortality 10. Still, despite recommendations against the use of specific vitamins to prevent 55 
disease 11, the prevalence of VMS use is increasing in Europe and the USA 12-14. Interestingly, VMS and 56 
dietary supplements (DS) use appears to be a fairly unstable behaviour in the general population, with high 57 
rates of initiation or discontinuing 15. Several socio-demographic characteristics such as female gender, older 58 
age and lower body mass index have been shown to be associated with consistent VMS use 15, but the 59 
number of studies that assessed trends and determinants of VMS and DS use are relatively scarce 15, 16. 60 
In a previous study, we showed that a sizable fraction of the Lausanne population consumed VMS or 61 
DS 17. We now assessed trends in VMS and DS use and the factors associated with initiation, discontinuing 62 
and persistence of in VMS and DS use in the population of Lausanne, Switzerland. 63 
MATERIALS AND METHODS 64 
Sampling 65 
The CoLaus Study is a prospective study aiming to assess the prevalence of cardiovascular risk 66 
factors and to identify new molecular determinants of these risk factors in the population of the city of 67 
Lausanne, Switzerland. The sampling procedure of the CoLaus Study has been described previously 18. In 68 
summary, a simple, non-stratified random sample of the overall population of Lausanne was drawn. The 69 
following inclusion criteria were applied: (a) written informed consent and (b) willingness to take part in the 70 
examination and to provide blood samples. Recruitment began in June 2003 and ended in May 2006 and 71 
included 6184 Caucasian participants. The evaluation included an interview, a physical exam, blood 72 
sampling and a set of questionnaires. The follow-up was performed between April 2009 and September 73 
2012, five and a half years on average after the collection of baseline data and was similar to the baseline 74 
evaluation. 75 
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Vitamin/mineral and dietary supplements 76 
Vitamin/mineral supplements were defined as previously 17. VMS and DS, including omega-3 77 
supplements, were identified. Specific combinations of calcium and vitamin D were also identified. 78 
For each group (VMS and DS) users were categorized as never (absent at baseline and follow-up), 79 
initiators (absent at baseline but present at follow-up), discontinuers (present at baseline but absent at follow-80 
up) and continuers (present at baseline and follow-up) as performed in other studies conducted in 81 
antihypertensive drug treatment 19, 20. In the prospective survey, drugs prescribed by a doctor were 82 
differentiated from those bought over-the-counter. As calcium + vitamin D supplements might be prescribed 83 
for osteoporosis prevention and iron ± vitamin B12 for anaemia, sensitivity analyses were carried excluding 84 
participants taking such combinations. Also for sensitivity analyses, participants were categorized as never, 85 
inconsistent (initiators or discontinuers) or consistent (continuers) users, as performed previously 15. 86 
Other data 87 
Educational level was categorized into mandatory school, apprenticeship, high school and university. 88 
Marital status was categorized into single/divorced/widowed and married/cohabitating. Country of birth was 89 
categorized into Swiss-born and born in another country. Smoking status was defined as never, former and 90 
current. . A participant was considered as physically active if he/she practiced at least twice per week leisure-91 
time physical activities with a minimal duration of 20 minutes. 92 
As presence of cardiovascular risk factors has been associated with initiation or maintenance of 93 
VMS 15, awareness of hypertension, dyslipidemia or diabetes was considered if the participant responded 94 
positively to the questions “did a doctor tell you that you were hypertensive / had high cholesterol levels / 95 
were diabetic?” respectively. No data was collected regarding other diseases such as arthrosis, cancer or 96 
osteoporosis. 97 
Body weight and height were measured with participants standing without shoes in light indoor 98 
clothes. Body weight was measured in kilograms to the nearest 100 g using a Seca® scale, which was 99 
calibrated regularly. Height was measured to the nearest 5 mm using a Seca® height gauge. Overweight was 100 
defined as body mass index (BMI) ≥25 and <30 kg/m2 and obesity as BMI≥30 kg/m2. As the number of 101 
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underweight (BMI<18.5 kg/m2) participants was very small (N=83 or 1.8% of the total sample), they were 102 
included in a “normal + underweight” category. 103 
Statistical analysis 104 
Participants were excluded if (a) they did not participate in the follow-up survey and (b) they had any 105 
missing socio-demographic data. Statistical analyses were performed using Stata version 13.1 for windows 106 
(Stata Corp, College Station, TX, USA). Descriptive results were expressed as number of participants 107 
(percentage) or as mean±standard deviation. Bivariate analyses were performed using chi-square for 108 
categorical variables and Student’s t-test or analysis of variance for continuous variables. For continuous 109 
variables, post-hoc pairwise comparisons using the method of Scheffe were performed when the results of 110 
the ANOVA were statistically significant. In agreement with a previous study 15, multivariable analysis was 111 
performed with multinomial logistic regression using never users as the reference; the results were expressed 112 
as relative risk ratio (RRR) and 95% confidence interval (CI). Multi-collinearity of the dependent variables 113 
was tested using the collin function of Stata; variance inflation factors between 1.01 and 1.20 were obtained, 114 
suggesting that multi-collinearity was not present. Tests were two-sided and statistical significance was 115 
assessed for p<0.05. 116 
Ethics statement 117 
The CoLaus study was approved by the Institutional Ethics Committee of the University of 118 
Lausanne. The study was conducted according to the Declaration of Helsinki and all participants provided 119 
written informed consent prior to participating. 120 
RESULTS 121 
Selection procedure and characteristics of participants 122 
Of the initial 6184 participants at baseline, 1501 (24.3%) did not participate in the follow-up survey 123 
and 7 (0.1%) had missing socio-demographic data. The selection procedure is summarized in Figure 1 and 124 
the comparison between included and excluded participants is summarized in supplemental Table 1. 125 
Excluded participants were older, less frequently women, had a lower educational level, were less frequently  126 
born in Switzerland, were more frequently smokers, sedentary or obese and had a higher prevalence of self-127 
reported hypertension and diabetes than included participants. Prevalence of VMS and DS use was also 128 
lower among excluded participants (supplemental table 1). 129 
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Trends and determinants of vitamin/mineral supplement use 130 
Prevalence of VMS use was 20.6% at baseline and 20.3% at follow-up (p=0.69). During the 5.5 year 131 
study period, 559 (12.0%) participants discontinued; 545 (11.7%) initiated and 404 (8.6%) continued VMS 132 
use, while 3168 (67.8%) did not use any VMS at baseline and follow-up.  133 
The bivariate associations between socio-demographic and clinical factors and being never using, 134 
initiating, discontinuing or continuing VMS are summarized in supplemental table 2. Significant 135 
associations were found with gender, age, educational level, marital status, Swiss citizenship, physical 136 
activity and BMI categories. These associations were partly confirmed by multivariate analysis, the results of 137 
which are summarized in table 1. Men had a lower RRR of discontinuing, initiating or continuing VMS use. 138 
Older age and being physically active were associated with a higher RRR of initiating and continuing VMS 139 
use. Having a lower education or a higher BMI was associated with a lower RRR of discontinuing and 140 
continuing VMS use. Finally, presence of reported dyslipidemia was associated with a higher RRR of 141 
continuing VMS use (table 1). Similar findings were obtained when the analysis was split by gender (not 142 
shown). 143 
Trends and determinants of dietary supplements use 144 
Prevalence of DS use was 10.4% at baseline and decreased to 6.8% at follow-up (p<0.001). During 145 
the 5.5 year study period, 405 (8.7%) participants discontinued; 239 (5.1%) initiated and 81 (1.7%) 146 
continued DS use, while 3951 (84.5%) did not use any DS at baseline and follow-up. 147 
The bivariate associations between socio-demographic and clinical factors and being never using, 148 
initiating, discontinuing or continuing DS are summarized in supplemental table 3. Significant associations 149 
were found with gender, age, marital status, Swiss citizenship, smoking status, physical activity and BMI 150 
categories. These associations were partly confirmed by multivariate analysis, the results of which are 151 
summarized in table 2. Men had a lower RRR of discontinuing, initiating or continuing DS use. Older age 152 
was associated with a higher RRR of initiating, discontinuing and continuing DS use. Being physically active 153 
was associated with a higher RRR of initiating and continuing DS use. Swiss citizenship and being former 154 
smoker was associated with a higher RRR of discontinuing DS use (table 2). Similar findings were obtained 155 
when the analysis was split by gender (not shown). 156 
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Sensitivity analyses 157 
 The results of the sensitivity analysis on VMS use excluding calcium and vitamin D or iron and 158 
vitamin B12 combinations were similar to those obtained when the analysis included all VMS, except that 159 
some associations were no longer significant due to smaller sample sizes (not shown). 160 
The results of the sensitivity analysis on never, inconsistent (initiating or discontinuing) and 161 
consistent (continuing) use of VMS are summarized in supplemental tables 4 and 5. On bivariate analysis, 162 
inconsistent use of VMS was associated with age, BMI, gender, educational level, marital and physical 163 
activity status (supplemental table 4). Multivariate analysis showed that participants of male gender, lower 164 
education, married or obese had a lower RRR of inconsistent users, while older or physically active 165 
participants had a higher RRR of inconsistent use (supplemental table 5). Similar findings were obtained 166 
when the analysis was split by gender (not shown). 167 
The results of the sensitivity analysis on never, inconsistent (initiating or discontinuing) and 168 
consistent (continuing) use of DS are summarized in supplemental tables 6 and 7. On bivariate analysis, 169 
inconsistent use of DS was associated with age, BMI, gender, educational level, country of birth, smoking, 170 
marital and physical activity status (supplemental table 6). Multivariate analysis showed that participants of 171 
male gender or of lower education had a lower RRR of inconsistent use, while older, former smoker or 172 
physically active participants had a higher RRR of inconsistent use (supplemental table 7). Similar findings 173 
were obtained when the analysis was split by gender (not shown). 174 
DISCUSSION 175 
VMS use changes with time, a sizable number of users discontinuing during a 5.5 year follow-up, 176 
being replaced by an almost similar number of previous never users initiating VMS, leading to a relatively 177 
stable number of VMS users. Conversely, the prevalence of DS use decreased significantly. 178 
Trends and determinants of vitamin/mineral supplement use 179 
Several cross-sectional and prospective studies have shown an increase in VMS use in the general 180 
population or in specific groups. In this study, VMS was relatively stable, the large number of participants 181 
discontinuing being compensated by an almost similar number of participants initiating VMS use. 182 
Interestingly, a large fraction of initiators was due to calcium and vitamin D combinations ant not to generic 183 
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VMS, suggesting that this increase was medically driven. These findings are partly in agreement with a 184 
previous study 15, with the difference that in the previous study the number of participants initiating VMS 185 
outweighed the number of participants discontinuing. Overall, our results indicate that individuals can be 186 
categorized either as VMS users or never users depending on the study period, and that VMS continuers are 187 
only a small fraction of prevalent VMS users. 188 
Women and older age were significantly associated with both initiating and continuing VMS use, a 189 
finding in agreement with the literature 15. A first explanation is that women and elderly people tend to be 190 
more health conscious and to adopt health-promoting behaviours such as VMS use. Another explanation is 191 
the prevention of osteoporosis in elderly women by vitamin D + calcium combinations. Indeed, among 192 
women, 273 (10.9% of all women, 71.6% of all women initiators) initiated the vitamin D + calcium 193 
combination, versus 63 (2.5% of all women, 11.3% of all women discontinuers) who discontinued. Thus, and 194 
in agreement with another study 16, our results suggest that most women VMS initiators did so for a medical 195 
and not for a personal reason. 196 
Being physically active was associated with both the initiation and the continuation of VMS, a 197 
finding also reported elsewhere 15. Physically active people tend to be more health-conscious and to adopt 198 
more frequently healthy eating and VMS use 21. Whether physically active people initiated VMS to promote 199 
their health or to improve physical performance remains to be assessed. 200 
In the sensitivity analyses, participants of lower education had a lower RRR of inconsistent 201 
(initiating or discontinuing) or consistent (continuing) VMS use, a finding partly in agreement with a 202 
previous study 15, where such associations were found in men only. Interestingly, when inconsistent users 203 
were split into initiators and discontinuers, the association with education was for discontinuing VMS only. 204 
The lower likelihood of discontinuing VMS among less educated people might be explained by the fact that 205 
participants with higher education consume more non-prescribed medicines 22, and thus change consumption 206 
more frequently. 207 
Presence of disease has been shown to increase the initiation of VMS by patients 15, although this 208 
statement has been challenged 23. Still, in this study, no consistent associations were found between self-209 
reported hypertension, dyslipidemic or diabetic status and initiation of VMS. Interestingly, participants who 210 
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reported dyslipidemia had a higher RRR of continuing VMS, a finding also reported elsewhere 15. Although 211 
some studies have shown a small effect of VMS on lipid levels 24 or carotid atherosclerosis 25, still VMS use 212 
is not recommended for the primary prevention of cardiovascular disease 11. 213 
Trends and determinants of dietary supplements use 214 
Contrary to a study conducted in the USA 16 but in agreement with another conducted in Scandinavia 215 
26, the prevalence of DS users decreased. Possible explanations include the absence or low efficiency of DS 216 
27-30 and tighter regulations regarding their health claims 31. Still, it would be of interest that the decrease 217 
observed in this study could be confirmed by other independent studies. As for VMS, our results suggest that 218 
only a small fraction of all DS users continuously consumes them.15 A possible explanation is that people 219 
adopt DS based on their health promises 32, then discontinue when these benefits are not met or when side 220 
effects occur 33. Still, as the reasons for discontinuing were not collected, these explanations remain 221 
speculative. Also, the diversity of DS precluded any analysis of the associations between discontinuing DS 222 
and the type of DS used. Conversely, DS maintenance continuation could be due to the presence of an effect 223 
(or to the absence of adverse effects) of DS. Again, the reasons for continuation are unknown and it would be 224 
of interest that further studies focus on the reasons for initiating, continuing or discontinuing DS. 225 
Former smokers were more likely to be discontinuers than never or current smokers. It is possible 226 
that former smokers initially used DS as aid to prevent smoking relapse or to prevent weight gain induced by 227 
quitting smoking, then quit DS due to their relative inefficiency 34, 35. 228 
Physical activity was associated with DS initiation, discontinuing and continuation. If the findings 229 
regarding initiation and continuation are in agreement with the literature 15, 36, 37, the association of physical 230 
activity with DS discontinuing was unexpected. A possible explanation is that physically active participants 231 
initially relied on DS to boost their performances and discontinued if the DS did not met their expectations. 232 
As no information was collected regarding the reasons for discontinuing, this explanation should be 233 
confirmed in other studies. 234 
Implications for public health nutrition 235 
Our findings have several implications for public health nutrition. First, they confirm that both VMS 236 
and DS use is an unstable behaviour and that a sizable fraction of that discontinuers are replaced by 237 
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initiators. Thus, the overall effect of VMS or DS use on health outcomes might be considerably decreased. 238 
Indeed, our results may partly explain the lack of effect of VMS on mortality 9, as VMS intake might not 239 
have been consistent throughout the study period. Finally, the “cycling” of VMS or DS could also lead to the 240 
sporadic occurrence of side effects due to interactions of VMS or DS with prescribed drugs, with potentially 241 
major health consequences 38. 242 
Study limitations 243 
This study has several limitations worth acknowledging. First, excluded participants differed 244 
significantly from the included ones. Thus, it is likely that our results are based on a more health-conscious 245 
sample than the general population and that the prevalence estimates for VMS and DS use might be 246 
overestimated. Still, our drop-out rate (24.4%) is comparable to the one of a previous study assessing trends 247 
in VMS use (23.1%) 15. Second, no data on duration or amount of VMS or DS use was collected; hence, it is 248 
possible that our estimates for the prevalence of continuers might be overestimated, as during the follow-up 249 
period some participants could have undergone several cycles of use/non-use of VMS or DS. Thus, future 250 
studies should consider the number and duration of use/non-use cycles when assessing VMS or DS use. 251 
Third, no information was collected regarding the type, intensity, duration and patterns of physical activity, 252 
and only the status of being physically active was collected; hence, it is likely that this assessment might be 253 
too weak to draw precise conclusions regarding the impact of physical activity on VMS or DS changes. Still, 254 
physical activity was significantly associated with initiation of VMS or DS, suggesting that even raw 255 
evaluations of physical activity status can be used in such studies. Fourth, changes in the baseline 256 
independent variables during follow-up (i.e. age, educational level, BMI changes) were not taken into 257 
account in the multinomial logistic model; still using time varying variables would preclude comparison with 258 
similar studies 15, 38 and could differ according to the criteria used to define change (i.e. in BMI levels) 39. 259 
Finally, only data from Caucasian participants living in a Swiss city was available, and it is currently 260 
unknown if our findings apply to other ethnicities or to other countries; for instance, a prospective study 261 
conducted in UK women 40 showed a much higher frequency of consistent users (54%, vs. 8.6% in our 262 
study), while the frequency of inconsistent (initiation + discontinuation) users was comparable (25%, vs. 263 
23.6% in our study). Thus, the prevalence of never users, initiators, discontinuers and continuers might not 264 
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be comparable between countries. Still, as the factors associated with VMS and DS use appear to be 265 
independent of the cultural and ethnic context 36, 37, they might be extrapolated to other countries. 266 
Conclusion 267 
In this population-based sample of the city of Lausanne, the prevalence of VMS use remained stable, 268 
but this apparent stability was due to high and comparable discontinuing and initiation rates. Conversely, DS 269 
use appears to be decreasing. Being physically active favours the initiation of VMS or DS, and older age 270 
favours the initiation of VMS. 271 
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Initial sample 
N=6184 (100%) 
Final sample 
N=4676 (75.6%) 
Missing baseline data 
N=7 (0.1%) 
No follow-up 
N=1501(24.3%) 
 
 Figure 1: selection procedure. 
Table 1: multivariable associations between socio-demographic and clinical variables with changes in vitamin supplement use occurring between 2003-6 and 
2009-12, CoLaus study, Lausanne, Switzerland, all participants. 
Initiators Discontinuers Continuers 
N 545 559 404 
Gender (man vs. woman) 0.37 (0.30 - 0.46) *** 0.38 (0.31 - 0.47) *** 0.22 (0.17 - 0.29) *** 
Age groups 
[35-45[ 1 (ref.) 1 (ref.) 1 (ref.) 
[45-55[ 1.80 (1.38 - 2.36) *** 1.04 (0.82 - 1.31) 2.09 (1.44 - 3.04) *** 
[55-65[ 2.25 (1.71 - 2.96) *** 0.99 (0.77 - 1.28) 4.56 (3.19 - 6.50) *** 
[65+ 2.36 (1.70 - 3.28) *** 1.10 (0.80 - 1.53) 6.35 (4.28 - 9.44) *** 
Education 
University 1 (ref.) 1 (ref.) 1 (ref.) 
High school 0.99 (0.75 - 1.31) 0.77 (0.59 - 1.01) 1.03 (0.75 - 1.42) 
Apprenticeship 0.81 (0.62 - 1.06) 0.78 (0.60 - 1.00) * 0.66 (0.48 - 0.91) ** 
Mandatory 0.85 (0.61 - 1.17) 0.57 (0.41 - 0.78) *** 0.52 (0.35 - 0.78) *** 
Marital status (married/cohab vs. other) 0.81 (0.66 - 0.98) * 0.89 (0.73 - 1.08) 0.78 (0.62 - 0.98) 
 Born in Switzerland vs. other country 1.16 (0.94 - 1.44) 1.04 (0.85 - 1.28) 1.23 (0.96 - 1.59) 
Smoking 
Never 1 (ref.) 1 (ref.) 1 (ref.) 
Former 1.05 (0.85 - 1.31) 1.21 (0.97 - 1.49) 1.29 (1.00 - 1.66) 
Current 0.95 (0.75 - 1.21) 0.98 (0.78 - 1.25) 1.05 (0.79 - 1.41) 
Physically active (yes vs. no) 1.30 (1.07 - 1.59) ** 1.05 (0.87 - 1.28) 1.44 (1.13 - 1.82) ** 
BMI groups    
Normal + underweight 1 (ref.) 1 (ref.) 1 (ref.) 
Overweight 0.82 (0.66 - 1.02) 0.83 (0.67 - 1.02) 0.68 (0.53 - 0.88) ** 
Obese 0.81 (0.60 - 1.10) 0.59 (0.42 - 0.82) ** 0.65 (0.45 - 0.94) * 
Hypertension (yes vs. no) 1.14 (0.91 - 1.44) 1.11 (0.87 - 1.41) 0.88 (0.67 - 1.15) 
Dyslipidemia (yes vs. no) 0.89 (0.70 - 1.13) 1.08 (0.85 - 1.37) 1.34 (1.04 - 1.73) * 
Diabetes (yes vs. no) 1.53 (0.99 - 2.37) 1.08 (0.65 - 1.81) 1.29 (0.75 - 2.21) 
 
Results are expressed as relative risk ratio and (95% confidence interval). BMI, body mass index. Statistical analysis by multinomial logistic regression using 
never users as reference. *, p<0.05; **, p<0.01; ***, p<0.001. 
 
Table 2: multivariable associations between socio-demographic and clinical variables with changes in dietary supplement use occurring between 2003-6 and 
2009-12, CoLaus study, Lausanne, Switzerland, all participants. 
 Initiators Discontinuers Continuers 
N 239 405 81 
Gender (man vs. woman) 0.41 (0.30 - 0.56) *** 0.30 (0.23 - 0.39) *** 0.30 (0.17 - 0.53) * 
Age groups    
[35-45[ 1 (ref.) 1 (ref.) 1 (ref.) 
[45-55[ 1.38 (0.95 - 1.99) 1.47 (1.09 - 1.97) ** 2.42 (1.10 - 5.35) * 
[55-65[ 1.76 (1.22 - 2.55) ** 1.77 (1.31 - 2.39) *** 4.53 (2.13 - 9.65) *** 
[65+ 1.14 (0.70 - 1.87) 1.57 (1.09 - 2.27) * 3.14 (1.29 - 7.62) ** 
Education    
University 1 (ref.) 1 (ref.) 1 (ref.) 
High school 1.02 (0.70 - 1.49) 0.99 (0.73 - 1.35) 1.04 (0.53 - 2.03) 
Apprenticeship 0.76 (0.52 - 1.10) 0.79 (0.59 - 1.07) 0.88 (0.46 - 1.68) 
Mandatory 0.73 (0.45 - 1.18) 0.77 (0.53 - 1.11) 0.82 (0.36 - 1.84) 
Marital status (married/cohab vs. other) 0.75 (0.57 - 0.99) * 1.07 (0.85 - 1.33) 0.81 (0.51 - 1.29) 
Born in Switzerland vs. other country 1.37 (1.00 - 1.87) § 1.30 (1.02 - 1.66) * 1.23 (0.73 - 2.08) 
Smoking    
Never 1 (ref.) 1 (ref.) 1 (ref.) 
Former 1.22 (0.91 - 1.65) 1.31 (1.03 - 1.66) * 1.34 (0.81 - 2.21) 
Current 0.75 (0.52 - 1.08) 0.92 (0.69 - 1.21) 0.88 (0.48 - 1.64) 
Physically active (yes vs. no) 1.66 (1.23 - 2.24) *** 1.33 (1.06 - 1.66) * 1.84 (1.09 - 3.09) * 
BMI groups    
Normal + underweight 1 (ref.) 1 (ref.) 1 (ref.) 
Overweight 0.71 (0.52 - 0.98) * 1.00 (0.79 - 1.28) 0.75 (0.45 - 1.27) 
Obese 0.82 (0.52 - 1.30) 0.80 (0.55 - 1.16) 0.65 (0.29 - 1.46) 
Hypertension (yes vs. no) 0.77 (0.53 - 1.11) 0.91 (0.70 - 1.20) 0.96 (0.55 - 1.67) 
Dyslipidemia (yes vs. no) 0.96 (0.68 - 1.35) 1.02 (0.79 - 1.33) 1.24 (0.73 - 2.10) 
Diabetes (yes vs. no) 1.38 (0.69 - 2.77) 0.93 (0.51 - 1.70) 0.33 (0.04 - 2.46) 
 
Results are expressed as relative risk ratio and (95% confidence interval). BMI, body mass index. Statistical analysis by multinomial logistic regression using 
never users as reference. §, p=0.051; *, p<0.05; **, p<0.01; ***, p<0.001. 
 
ONLINE SUPPORTING MATERIAL 
Supplemental table 1: comparison of baseline characteristics between included and excluded 
participants 
 Included Excluded P-value 
N 4676 1508  
Woman 2505 (53.6) 746 (49.5) 0.006 
Age (years) 52.6 ± 10.6 54.6 ± 11.3 <0.001 
Age groups (%)   <0.001 
[35-45[ 1362 (29.1) 384 (25.5)  
[45-55[ 1365 (29.2) 393 (26.1)  
[55-65[ 1288 (27.5) 418 (27.7)  
[65+ 661 (14.1) 312 (20.7)  
Education (%)   <0.001 
University 939 (20.1) 201 (13.4)  
High school 1185 (25.3) 283 (18.8)  
Apprenticeship 1741 (37.2) 544 (36.2)  
Mandatory 811 (17.3) 475 (31.6)  
Married/cohabiting (%) 3152 (67.4) 982 (65.3) 0.122 
Born in Switzerland (%) 3164 (67.7) 838 (55.6) <0.001 
Smoking (%)   <0.001 
Never 1889 (40.4) 588 (39.0)  
Former 1580 (33.8) 452 (30.0)  
Current 1207 (25.8) 466 (30.9)  
Physically active (%) 2690 (57.5) 739 (49.1) <0.001 
Body mass index (kg/m2) 25.6 ± 4.4 26.5 ± 4.9 <0.001 
BMI groups (%)   <0.001 
Normal + underweight 2318 (49.6) 651 (43.2)  
Overweight 1705 (36.5) 548 (36.4)  
Obese 653 (14.0) 307 (20.4)  
Self-reported (%)    
Hypertension 1147 (24.5) 483 (32.1) <0.001 
Dyslipidemia 1087 (23.3) 383 (25.4) 0.086 
Diabetes 204 (4.4) 106 (7.0) <0.001 
Vitamin supplement use (%) 963 (20.6) 274 (18.2) 0.041 
 Dietary supplement use (%) 486 (10.4) 128 (8.5) 0.031 
Results are expressed as number of participants (percentage) or as average ± standard deviation. BMI, 
body mass index. Statistical analysis using chi-square or Student’s t-test. 
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Supplemental table 2: bivariate associations between socio-demographic and clinical variables with changes in vitamin supplement use occurring between 
2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland. 
 Never users Initiators Discontinuers Continuers P-value 
N (%) 3168 (67.8) 545 (11.7) 559 (12.0) 404 (8.6)  
Woman (%) 1425 (45.0) 381 (69.9) 379 (67.8) 320 (79.2) <0.001 
Age (years) 51.6 ± 10.5 a 55.1 ± 10.1 b 51.6 ± 10.6 a 58.4 ± 9.4 c <0.001 
Age groups (%)     <0.001 
[35-45[ 1034 (32.6) 102 (18.7) 179 (32.0) 47 (11.6)  
[45-55[ 941 (29.7) 166 (30.5) 170 (30.4) 88 (21.8)  
[55-65[ 803 (25.4) 183 (33.6) 138 (24.7) 164 (40.6)  
[65+ 390 (12.3) 94 (17.3) 72 (12.9) 105 (26.0)  
Education (%)     0.003 
University 625 (19.7) 104 (19.1) 134 (24.0) 76 (18.8)  
High school 770 (24.3) 146 (26.8) 139 (24.9) 130 (32.2)  
Apprenticeship 1191 (37.6) 197 (36.2) 210 (37.6) 143 (35.4)  
Mandatory 582 (18.4) 98 (18.0) 76 (13.6) 55 (13.6)  
Married/cohabiting (%) 2236 (70.6) 330 (60.6) 357 (63.9) 229 (56.7) <0.001 
Born in Switzerland (%) 2094 (66.1) 387 (71.0) 385 (68.9) 298 (73.8) 0.004 
Smoking (%)     0.195 
Never 1266 (40.0) 233 (42.8) 225 (40.3) 165 (40.8)  
Former 1049 (33.1) 183 (33.6) 197 (35.2) 151 (37.4)  
Current 853 (26.9) 129 (23.7) 137 (24.5) 88 (21.8)  
Physically active (%) 1735 (54.8) 345 (63.3) 332 (59.4) 278 (68.8) <0.001 
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Body mass index (kg/m2) 25.9 ± 4.3 a 25.3 ± 4.8 b 24.8 ± 4.3 b 24.7 ± 4.5 b <0.001 
BMI groups (%)     <0.001 
Normal + underweight 1463 (46.2) 293 (53.8) 323 (57.8) 239 (59.2)  
Overweight 1230 (38.8) 175 (32.1) 182 (32.6) 118 (29.2)  
Obese 475 (15.0) 77 (14.1) 54 (9.7) 47 (11.6)  
Self-reported (%)      
Hypertension 771 (24.3) 149 (27.3) 126 (22.5) 101 (25.0) 0.304 
Dyslipidemia 727 (23.0) 120 (22.0) 120 (21.5) 120 (29.7) 0.011 
Diabetes 136 (4.3) 30 (5.5) 19 (3.4) 19 (4.7) 0.377 
 
Results are expressed as number of participants (percentage) or as mean± standard deviation. BMI, body mass index. Statistical analysis using chi-square or 
analysis of variance. For continuous variables, post-hoc pairwise comparisons using the method of Scheffe were performed when the results of the ANOVA 
were statistically significant. Results with differing subscripts are significantly different at a p<0.05 level (corrected for multiple comparisons). 
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Supplemental table 3: bivariate associations between socio-demographic and clinical variables with changes in dietary supplement use occurring between 
2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland. 
 Never users Initiators Discontinuers Continuers P-value 
N (%) 3951 (84.5) 239 (5.1%) 405 (8.7) 81 (1.7)  
Woman (%) 1959 (49.6) 174 (72.8) 308 (76.1) 64 (79.0) <0.001 
Age (years) 52.2 ± 10.6 a 53.7 ± 9.9 b 54.5 ± 10.2 b 56.5 ± 9.7 b <0.001 
Age groups (%)     <0.001 
[35-45[ 1211 (30.7) 56 (23.4) 86 (21.2) 9 (11.1)  
[45-55[ 1152 (29.2) 71 (29.7) 121 (29.9) 21 (25.9)  
[55-65[ 1034 (26.2) 83 (34.7) 134 (33.1) 37 (45.7)  
[65+ 554 (14.0) 29 (12.1) 64 (15.8) 14 (17.3)  
Education (%)     0.285 
University 788 (19.9) 54 (22.6) 82 (20.3) 15 (18.5)  
High school 975 (24.7) 72 (30.1) 115 (28.4) 23 (28.4)  
Apprenticeship 1482 (37.5) 82 (34.3) 146 (36.1) 31 (38.3)  
Mandatory 706 (17.9) 31 (13.0) 62 (15.3) 12 (14.8)  
Married/cohabiting (%) 2707 (68.5) 138 (57.7) 261 (64.4) 46 (56.8) <0.001 
Born in Switzerland (%) 2630 (66.6) 178 (74.5) 296 (73.1) 60 (74.1) 0.003 
Smoking (%)     0.016 
Never 1590 (40.2) 102 (42.7) 164 (40.5) 33 (40.7)  
Former 1302 (33.0) 91 (38.1) 155 (38.3) 32 (39.5)  
Current 1059 (26.8) 46 (19.3) 86 (21.2) 16 (19.8)  
Physically active (%) 2194 (55.5) 170 (71.1) 266 (65.7) 60 (74.1) <0.001 
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Body mass index (kg/m2) 25.8 ± 4.4 a 24.7 ± 4.7 b 24.9 ± 4.2 b 24.5 ± 4.7 a, b <0.001 
BMI groups (%)     <0.001 
Normal + underweight 1897 (48.0) 148 (61.9) 224 (55.3) 49 (60.5)  
Overweight 1481 (37.5) 63 (26.4) 137 (33.8) 24 (29.6)  
Obese 573 (14.5) 28 (11.7) 44 (10.9) 8 (9.9)  
Self-reported (%)      
Hypertension 990 (25.1) 46 (19.3) 91 (22.5) 20 (24.7) 0.163 
Dyslipidemia 924 (23.4) 49 (20.5) 92 (22.7) 22 (27.2) 0.612 
Diabetes 180 (4.6) 10 (4.2) 13 (3.2) 1 (1.2) NA 
 
Results are expressed as number of participants (percentage) or as mean± standard deviation. BMI, body mass index, NA, not assessable. Statistical analysis 
using chi-square or analysis of variance. For continuous variables, post-hoc pairwise comparisons using the method of Scheffe were performed when the 
results of the ANOVA were statistically significant. Results with differing subscripts are significantly different at a p<0.05 level (corrected for multiple 
comparisons) 
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Supplemental table 4: bivariate associations between socio-demographic and clinical variables with 
changes in vitamin supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, 
Switzerland. 
 Never Inconsistent Consistent P-value 
N (%) 3168 (67.8) 1104 (23.6) 404 (8.6)  
Woman (%) 1425 (45.0) 760 (68.8) 320 (79.2) <0.001 
Age (years) 51.6 ± 10.5 53.3 ± 10.5 58.4 ± 9.4 <0.001 
Age groups (%)    <0.001 
[35-45[ 1034 (32.6) 281 (25.5) 47 (11.6)  
[45-55[ 941 (29.7) 336 (30.4) 88 (21.8)  
[55-65[ 803 (25.4) 321 (29.1) 164 (40.6)  
[65+ 390 (12.3) 166 (15.0) 105 (26.0)  
Education (%)    0.007 
University 625 (19.7) 238 (21.6) 76 (18.8)  
High school 770 (24.3) 285 (25.8) 130 (32.2)  
Apprenticeship 1191 (37.6) 407 (36.9) 143 (35.4)  
Mandatory 582 (18.4) 174 (15.8) 55 (13.6)  
Married/cohabiting (%) 2236 (70.6) 687 (62.2) 229 (56.7) <0.001 
Born in Switzerland (%) 2094 (66.1) 772 (69.9) 298 (73.8) 0.002 
Smoking (%)    0.095 
Never 1266 (40.0) 458 (41.5) 165 (40.8)  
Former 1049 (33.1) 380 (34.4) 151 (37.4)  
Current 853 (26.9) 266 (24.1) 88 (21.8)  
Physically active (%) 1735 (54.8) 677 (61.3) 278 (68.8) <0.001 
Body mass index (kg/m2) 25.9 ± 4.3 25.1 ± 4.6 24.7 ± 4.5 <0.001 
BMI groups (%)    <0.001 
Normal + underweight 1463 (46.2) 616 (55.8) 239 (59.2)  
Overweight 1230 (38.8) 357 (32.3) 118 (29.2)  
Obese 475 (15.0) 131 (11.9) 47 (11.6)  
Self-reported (%)     
Hypertension 771 (24.3) 275 (24.9) 101 (25.0) 0.906 
Dyslipidemia 727 (23.0) 240 (21.7) 120 (29.7) 0.004 
Diabetes 136 (4.3) 49 (4.4) 19 (4.7) 0.921 
 
Results are expressed as number of participants (percentage) or as average ±standard deviation. BMI, 
body mass index. Inconsistent=initiating or discontinuing; consistent=continuing. Statistical analysis 
using chi-square or analysis of variance.
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Supplemental table 5: multivariable associations between socio-demographic and clinical variables 
with changes in vitamin supplement use occurring between 2003-6 and 2009-12, CoLaus study, 
Lausanne, Switzerland, all participants. 
 Inconsistent Consistent 
N 1104 404 
Gender (man vs. woman) 0.38 (0.32 - 0.44) *** 0.22 (0.17 - 0.29) *** 
Age groups   
[35-45[ 1 (ref.) 1 (ref.) 
[45-55[ 1.32 (1.09 - 1.59) ** 2.09 (1.44 - 3.03) *** 
[55-65[ 1.45 (1.19 - 1.77) *** 4.55 (3.19 - 6.50) *** 
[65+ 1.57 (1.22 - 2.01) *** 6.35 (4.28 - 9.44) *** 
Education   
University 1 (ref.) 1 (ref.) 
High school 0.87 (0.70 - 1.07) 1.02 (0.74 - 1.41) 
Apprenticeship 0.79 (0.65 - 0.96) * 0.66 (0.48 - 0.91) ** 
Mandatory 0.69 (0.54 - 0.89) ** 0.52 (0.35 - 0.77) *** 
Marital status (married/cohab vs. other) 0.85 (0.73 - 0.99) * 0.78 (0.63 - 0.98) * 
 Born in Switzerland vs. in other country 1.10 (0.94 - 1.29) 1.23 (0.96 - 1.59) 
Smoking   
Never 1 (ref.) 1 (ref.) 
Former 1.13 (0.96 - 1.33) 1.29 (1.01 - 1.66) 
Current 0.97 (0.81 - 1.16) 1.05 (0.79 - 1.41) 
Physically active (yes vs. no) 1.17 (1.01 - 1.36) * 1.43 (1.13 - 1.82) ** 
BMI groups   
Normal + underweight 1 (ref.) 1 (ref.) 
Overweight 0.82 (0.70 - 0.97) 0.68 (0.53 - 0.88) ** 
Obese 0.70 (0.55 - 0.89) ** 0.64 (0.44 - 0.94) * 
Hypertension (yes vs. no) 1.13 (0.94 - 1.35) 0.88 (0.67 - 1.15) 
Dyslipidemia (yes vs. no) 0.98 (0.82 - 1.17) 1.34 (1.04 - 1.73) * 
Diabetes (yes vs. no) 1.31 (0.92 - 1.88) 1.29 (0.75 - 2.21) 
 
Results are expressed as relative risk ratio and (95% confidence interval). BMI, body mass index. 
Inconsistent=initiating or discontinuing; consistent=continuing. Statistical analysis by multinomial 
logistic regression using never users as reference. *, p<0.05; **, p<0.01; ***, p<0.001.  
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Supplemental table 6: bivariate associations between socio-demographic and clinical variables with 
changes in dietary supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, 
Switzerland. 
 Never Inconsistent Consistent P-value 
N (%) 3951 (84.5) 644 (13.8) 81 (1.7)  
Woman (%) 1959 (49.6) 482 (74.8) 64 (79.0) <0.001 
Age (years) 52.2 ± 10.6 54.2 ± 10.1 56.5 ± 9.7 <0.001 
Age groups (%)    <0.001 
[35-45[ 1211 (30.7) 142 (22.1) 9 (11.1)  
[45-55[ 1152 (29.2) 192 (29.8) 21 (25.9)  
[55-65[ 1034 (26.2) 217 (33.7) 37 (45.7)  
[65+ 554 (14.0) 93 (14.4) 14 (17.3)  
Education (%)    0.139 
University 788 (19.9) 136 (21.1) 15 (18.5)  
High school 975 (24.7) 187 (29.0) 23 (28.4)  
Apprenticeship 1482 (37.5) 228 (35.4) 31 (38.3)  
Mandatory 706 (17.9) 93 (14.4) 12 (14.8)  
Married/cohabiting (%) 2707 (68.5) 399 (62.0) 46 (56.8) 0.001 
Born in Switzerland (%) 2630 (66.6) 474 (73.6) 60 (74.1) 0.001 
Smoking (%)    0.004 
Never 1590 (40.2) 266 (41.3) 33 (40.7)  
Former 1302 (33.0) 246 (38.2) 32 (39.5)  
Current 1059 (26.8) 132 (20.5) 16 (19.8)  
Physically active (%) 2194 (55.5) 436 (67.7) 60 (74.1)  
Body mass index (kg/m2) 25.8 ± 4.4 24.8 ± 4.4 24.5 ± 4.7 <0.001 
BMI groups (%)    <0.001 
Normal + underweight 1897 (48.0) 372 (57.8) 49 (60.5)  
Overweight 1481 (37.5) 200 (31.1) 24 (29.6)  
Obese 573 (14.5) 72 (11.2) 8 (9.9)  
Self-reported (%)     
Hypertension 990 (25.1) 137 (21.3) 20 (24.7) 0.117 
Dyslipidemia 924 (23.4) 141 (21.9) 22 (27.2) 0.497 
Diabetes 180 (4.6) 23 (3.6) 1 (1.2) NA 
 
Results are expressed as number of participants (percentage) or as mean±standard deviation. BMI, 
body mass index. Inconsistent=initiating or discontinuing; consistent=continuing. Statistical analysis 
using chi-square or analysis of variance.NA, not assessable.
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Supplemental table 7: multivariable associations between socio-demographic and clinical variables 
with changes in dietary supplement use occurring between 2003-6 and 2009-12, CoLaus study, 
Lausanne, Switzerland, all participants. 
 Inconsistent Consistent 
N 644 81 
Gender (man vs. woman) 0.34 (0.28 - 0.41) *** 0.30 (0.17 - 0.53) *** 
Age groups   
[35-45[ 1 (ref.) 1 (ref.) 
[45-55[ 1.43 (1.13 - 1.82) ** 2.42 (1.10 - 5.35) * 
[55-65[ 1.76 (1.38 - 2.25) *** 4.53 (2.13 - 9.65) *** 
[65+ 1.40 (1.03 - 1.90) * 3.14 (1.29 - 7.62) ** 
Education   
University 1 (ref.) 1 (ref.) 
High school 1.00 (0.78 - 1.29) 1.04 (0.53 - 2.03) 
Apprenticeship 0.78 (0.61 - 1.00) * 0.88 (0.46 - 1.68) 
Mandatory 0.75 (0.56 - 1.02) 0.82 (0.36 - 1.84) 
Marital status (married/cohab vs. other) 0.94 (0.78 - 1.12) 0.81 (0.51 - 1.29) 
 Born in Switzerland vs. other country 1.33 (1.09 - 1.62) ** 1.23 (0.73 - 2.08) 
Smoking   
Never 1 (ref.) 1 (ref.) 
Former 1.28 (1.05 - 1.55) * 1.34 (0.81 - 2.21) 
Current 0.85 (0.67 - 1.07) 0.88 (0.48 - 1.64) 
Physically active (yes vs. no) 1.44 (1.19 - 1.73) *** 1.84 (1.09 - 3.09) * 
BMI groups   
Normal + underweight 1 (ref.) 1 (ref.) 
Overweight 0.89 (0.73 - 1.08) 0.75 (0.45 - 1.27) 
Obese 0.81 (0.60 - 1.09) 0.65 (0.29 - 1.46) 
Hypertension (yes vs. no) 0.86 (0.69 - 1.08) 0.96 (0.55 - 1.67) 
Dyslipidemia (yes vs. no) 1.00 (0.80 - 1.24) 1.24 (0.73 - 2.10) 
Diabetes (yes vs. no) 1.09 (0.68 - 1.74) 0.33 (0.04 - 2.46) 
 
Results are expressed as relative risk ratio and (95% confidence interval). BMI, body mass index. 
Inconsistent=initiating or discontinuing; consistent=continuing. Statistical analysis by multinomial 
logistic regression using never users as reference. *, p<0.05; **, p<0.01; ***, p<0.001. 
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